US Patent 10,035,788: Neratinib Maleate Polymorph Claims, Patent Scope, Exclusivity and Generic Risk
US Patent 10,035,788 protects methods of treating cancer with specific crystalline forms of neratinib maleate, rather than neratinib generally. The patent covers an anhydrous form, a monohydrate form, their defined X-ray diffraction profiles, a claimed two-fold exposure advantage over neratinib free base, selected cancer indications, reduced diarrhea or emetic-receptor interactions, and specified crystallization processes. Its commercial relevance depends on whether the marketed neratinib product uses one of the claimed solid forms and whether the patent is listed for the approved product.
What does US Patent 10,035,788 protect?
The patent protects two related crystalline forms of neratinib maleate:
| Claim group |
Protected subject matter |
Key limitation |
| Claims 1-12 |
Treatment using anhydrous neratinib maleate |
Specific XRPD peaks and at least two-fold greater AUC than neratinib free base |
| Claims 13-24 |
Treatment using neratinib maleate monohydrate |
Specific XRPD peaks and at least two-fold greater AUC than neratinib free base |
| Claims 2-5 |
More detailed identification of the anhydrous form |
Expanded peak lists or substantially matching XRPD patterns |
| Claims 14-17 |
More detailed identification of the monohydrate form |
Expanded peak lists or substantially matching XRPD patterns |
| Claims 6-8 and 18-20 |
Cancer subgroups |
Breast, lung, and specified additional cancers |
| Claims 9-10 and 21-22 |
Clinical or pharmacological effects |
Reduced emetic-receptor interactions or diarrhea |
| Claims 11-12 |
Preparation and drying of anhydrous form |
Conversion of monohydrate under specified vacuum-drying conditions |
| Claims 23-24 |
Preparation of monohydrate |
Water-alcohol crystallization with approximately 2.5% to 2.7% water |
The claims do not broadly cover every use of neratinib, every neratinib salt, or every neratinib formulation. They are directed to treatment with particular solid-state forms of neratinib maleate.
The patent identifies neratinib by its full chemical name, but the active pharmaceutical ingredient is commonly referred to as neratinib. The marketed product is NERLYNX, an oral neratinib maleate tablet approved by the FDA for extended adjuvant treatment of adults with early-stage HER2-overexpressed or HER2-amplified breast cancer following adjuvant trastuzumab-based therapy.[1]
How do the anhydrous and monohydrate claims differ?
The two independent claim families protect different solid forms with different XRPD fingerprints.
| Feature |
Anhydrous form |
Monohydrate form |
| Independent method claim |
Claim 1 |
Claim 13 |
| Solid form |
Anhydrous neratinib maleate |
Neratinib maleate monohydrate |
| Core XRPD peaks |
6.16, 7.38, 8.75, 12.61, 14.65, 15.75° 2θ |
6.53, 8.43, 12.19, 12.47, 13.01, 16.76, 21.11° 2θ |
| Peak tolerance |
±0.20° 2θ |
±0.20° 2θ |
| Exposure limitation |
At least two-fold greater AUC than free-base neratinib |
At least two-fold greater AUC than free-base neratinib |
| Detailed pattern claim |
Claims 2-5 |
Claims 14-17 |
| Manufacturing claims |
Claims 11-12 |
Claims 23-24 |
The anhydrous form is defined through a conversion process that begins with the monohydrate. The process requires vacuum drying at a temperature above 30°C for 12 to 48 hours. Claim 12 narrows this to drying at 50°C and 10 mm Hg for 24 hours.
The monohydrate is produced by dissolving neratinib and maleic acid in a water-alcohol solution, holding the mixture at approximately 40°C, cooling it to room temperature, and filtering the precipitated material. Claim 24 requires a water content of approximately 2.5% to 2.7% by weight.
What is the technical scope of the XRPD limitations?
The X-ray diffraction limitations are central to infringement analysis. A product cannot be assessed solely by its chemical name or salt designation. The relevant question is whether the solid material administered to patients exhibits the claimed diffraction pattern within the stated ±0.20° 2θ tolerance.
The claim structure creates several levels of proof:
- The defendant’s material must be neratinib maleate.
- The material must be the claimed anhydrous or monohydrate form.
- The material must display the required XRPD peaks.
- The method must involve administering that form to a patient for cancer treatment.
- The anhydrous and monohydrate independent claims also require the stated two-fold AUC comparison.
Claims 4, 5, 16, and 17 refer to substantially the XRPD pattern shown in patent figures. Those claims may create evidentiary questions concerning the meaning of “substantially,” the measurement conditions, instrument variation, sample preparation, and whether the accused product has undergone hydration, dehydration, or polymorphic conversion.
The XRPD claims are narrower than claims based only on chemical identity. A generic manufacturer could potentially avoid literal infringement if it uses a different polymorph, amorphous material, different salt, or formulation that does not produce the claimed XRPD pattern. That strategy would still be subject to other patents covering neratinib, its approved use, manufacturing, or different solid forms.
Does the patent cover NERLYNX?
The patent’s commercial coverage depends on the solid form used in NERLYNX tablets and on the scope of the FDA-approved product’s patent listings.
The FDA label identifies NERLYNX as neratinib maleate tablets and describes the product as containing 40 mg of neratinib.[1] The label alone does not establish which crystalline form is present. That determination generally requires regulatory chemistry, manufacturing and controls documentation, patent specifications, product samples, or analytical testing.
If NERLYNX contains the patented anhydrous or monohydrate form, a generic applicant seeking approval for a therapeutically equivalent product may face a product-specific patent challenge. If the commercial tablet contains a different solid form or if the relevant claims are not listed for the product, the practical impact of US 10,035,788 may be lower.
When does US Patent 10,035,788 expire?
US Patent 10,035,788 was issued on July 31, 2018.[2] Its term is generally measured from the relevant nonprovisional application or international filing date, subject to patent-term adjustment, terminal disclaimers, and other statutory corrections.
Public patent records associate the patent family with a 2014 filing period and a 2013 priority history. On that basis, the nominal expiration is expected to fall in March 2034, before any applicable patent-term adjustment. The legally operative expiration date should be taken from the USPTO patent record and any terminal-disclaimer or patent-term-adjustment data, not calculated solely from the issue date.[2,3]
| Event |
Date or period |
| Earliest reported priority period |
March 2013 |
| US filing period |
March 2014 |
| Patent issued |
July 31, 2018 |
| Expected nominal term endpoint |
March 2034, subject to PTA and related adjustments |
| FDA NERLYNX regulatory exclusivity |
Separate from patent term and dependent on the applicable FDA exclusivity records |
The patent does not receive a new patent term merely because the claims cover a later-discovered polymorph. Its expiration remains tied to the applicable patent-family filing rules.
What is the Orange Book status of US Patent 10,035,788?
The Orange Book status must be evaluated against the specific NDA and product listing for NERLYNX. FDA-listed patents can include composition, formulation, method-of-use, and drug-substance patents, but FDA listing does not determine ultimate validity or infringement.[3]
US 10,035,788 is commercially relevant to the Orange Book only if the NDA holder submitted it as a patent that claims the approved drug, an approved method of use, or a qualifying formulation under FDA listing rules. The claim set is drafted as treatment claims, not as a conventional composition claim. Its listing position would therefore depend on whether the claimed crystalline form and treatment method correspond to the approved product and labeling.
A review of the current Orange Book patent table is required for a definitive active, expired, delisted, or withdrawn status. The patent text alone cannot establish that status.
What Paragraph IV risks does this patent create?
An ANDA applicant may challenge an Orange Book-listed patent by submitting a Paragraph IV certification asserting that the patent is invalid, unenforceable, or will not be infringed. The relevant risk theories include:
Noninfringement
A generic applicant may argue that its product:
- Uses a different neratinib polymorph.
- Uses an amorphous or non-crystalline form.
- Does not exhibit the required XRPD peaks.
- Does not meet the claimed AUC limitation.
- Is not administered in a manner covered by the method claims.
- Does not satisfy the specified cancer indication or labeling language.
The XRPD limitations provide a potentially strong noninfringement pathway if the generic manufacturer can select and control a distinct solid form.
Invalidity
Potential invalidity theories may include:
- Anticipation or obviousness based on earlier neratinib maleate forms.
- Obviousness based on known salt screening and polymorph-screening techniques.
- Lack of written description or enablement for the claimed XRPD ranges.
- Indefiniteness involving “substantially” matching patterns.
- Lack of credible support for the two-fold AUC limitation across the full scope of the claims.
- Inconsistency between the monohydrate designation in claim 13 and the reference to anhydrous material in its pharmacokinetic limitation.
The AUC limitation may narrow the claims but also create proof issues. A challenger could argue that the patent does not establish that every formulation meeting the structural limitation produces at least twice the exposure of free-base neratinib under all relevant administration conditions.
Enforcement considerations
Because claims 1 and 13 are method claims, infringement may depend on the generic product’s proposed labeling and instructions for use. A label that encourages treatment of the claimed cancers with the claimed solid form could support induced-infringement theories if the underlying patent is valid and enforceable.
Does the patent protect reduced diarrhea or improved tolerability?
Claims 9, 10, 21, and 22 add functional limitations concerning reduced emetic-receptor interactions or reduced diarrhea relative to free-base neratinib.
These claims do not broadly claim the clinical management of neratinib-associated diarrhea. They require administration of the specified crystalline maleate form and the claimed comparative effect. A product may therefore fall within the broader independent claim without satisfying the narrower diarrhea or emetic-receptor claims.
The clinical significance is relevant because diarrhea is a major tolerability issue identified in the NERLYNX prescribing information. The FDA label recommends antidiarrheal prophylaxis during early treatment and provides dose-management instructions for severe or persistent diarrhea.[1] The patent attempts to connect the solid-state form to improved exposure and tolerability, but the claims do not replace the label’s prophylactic or dose-modification requirements.
What manufacturing and intellectual-property barriers does the patent create?
The manufacturing claims are narrower than the treatment claims and cover defined crystallization operations.
Monohydrate process
Claim 23 requires:
- Neratinib and maleic acid.
- A water-alcohol solvent system.
- Initial mixing at approximately 50°C to 60°C.
- Holding at approximately 40°C for about 12 hours.
- Cooling to approximately 25°C over at least four hours.
- Further holding at room temperature for at least two hours.
- Filtration to obtain the monohydrate.
Claim 24 adds the water-content range of approximately 2.5% to 2.7%.
Anhydrous process
Claim 11 incorporates the monohydrate process and then requires:
- Vacuum drying.
- A temperature above 30°C.
- Drying for 12 to 48 hours.
Claim 12 specifies 50°C, 10 mm Hg, and 24 hours.
A generic manufacturer could reduce process-claim exposure by using a different solvent system, crystallization temperature, cooling profile, seeding approach, or drying process. That would not automatically avoid the treatment claims if the final administered product still has the claimed XRPD profile.
How strong is the patent estate for neratinib?
US 10,035,788 is a specialized solid-state patent. Its strength is highest where the following facts align:
- The branded product contains the claimed neratinib maleate form.
- The form is stable and reproducible in commercial manufacture.
- The claimed XRPD peaks are analytically distinctive.
- The AUC advantage is supported by reliable comparative studies.
- The patent is listed for the approved product.
- The generic applicant’s proposed product uses the same solid form.
Its strength is lower if the commercial product uses an unclaimed form, if the two-fold AUC limitation is difficult to prove, or if a generic manufacturer can use a noninfringing polymorph while retaining pharmaceutical equivalence.
The patent does not create biosimilar risk because neratinib is a chemically synthesized small-molecule drug. The relevant pathway is an ANDA, not a biosimilar application under the Public Health Service Act. Generic risk therefore turns on Hatch-Waxman certifications, Orange Book listings, patent litigation, and approval timing.[3]
What is the competitive and revenue impact?
NERLYNX competes in the HER2-positive breast-cancer market with antibody and antibody-drug-conjugate therapies, including trastuzumab-based regimens, pertuzumab, ado-trastuzumab emtansine, and trastuzumab deruxtecan. Neratinib’s principal commercial differentiation is oral administration and extended adjuvant use after trastuzumab-based therapy.[1]
The revenue exposure from this patent is not equivalent to the entire NERLYNX franchise. The patent protects only products and uses meeting the crystalline-form and comparative-exposure limitations. Its commercial value is greatest if the patent blocks an ANDA product using the same approved solid form. It is less effective against a carefully engineered generic using a different solid-state form.
No reliable revenue amount can be assigned from the patent claims alone. Revenue exposure requires product sales, market share, treatment duration, generic filing activity, patent-listing data, and any settlement or launch agreement.
What patent litigation or settlement agreements affect US 10,035,788?
The supplied claim text does not establish a Paragraph IV notice, district-court complaint, PTAB proceeding, settlement agreement, or authorized-generic arrangement involving US 10,035,788.
A complete litigation assessment must distinguish between:
- Challenges to this patent specifically.
- Litigation involving other NERLYNX patents.
- Patent-term or Orange Book disputes.
- PTAB validity proceedings.
- Commercial settlements that may permit an agreed generic launch date.
The existence of litigation against another neratinib patent would not establish a challenge to US 10,035,788.
Key Takeaways
- US 10,035,788 is a crystalline-form and method-of-treatment patent for neratinib maleate.
- Claims 1-12 cover anhydrous neratinib maleate; claims 13-24 cover the monohydrate.
- The claims rely heavily on XRPD peak patterns, not merely the chemical identity of neratinib maleate.
- The independent claims require at least a two-fold AUC increase versus neratinib free base.
- The patent includes narrower claims directed to reduced diarrhea, reduced emetic-receptor interactions, selected cancers, and specified manufacturing conditions.
- The expected nominal expiration is in March 2034, subject to USPTO patent-term data and any terminal disclaimer.
- Generic risk is primarily an ANDA and Paragraph IV issue, not a biosimilar issue.
- The patent’s practical blocking power depends on whether NERLYNX uses the claimed form and whether FDA has accepted the patent for Orange Book listing.
- A generic using a different polymorph may have a credible design-around position, but it must assess the broader neratinib patent estate.
FAQs
Does US Patent 10,035,788 cover neratinib free base?
No. The claims require crystalline neratinib maleate in either the anhydrous or monohydrate form. Neratinib free base is used as the comparator for the AUC limitation.
Can a generic avoid this patent by using a different neratinib salt?
Potentially, with respect to this patent. A different salt would generally not satisfy the claimed neratinib maleate limitation, but other patents or regulatory requirements could still affect approval.
Are the XRPD peaks required for infringement?
Yes. The independent claims require the specified crystalline form, which is defined by the listed XRPD peaks. Analytical testing would be central to a product-form infringement dispute.
Does this patent claim a treatment for all breast cancer?
No. It claims treatment methods using the specified neratinib maleate forms. Breast cancer is a dependent indication, and the approved NERLYNX indication is narrower than all breast cancer treatment.
Is a neratinib generic required to conduct a Paragraph IV analysis for this patent?
Only if the patent is listed in the Orange Book for the relevant NERLYNX NDA and remains applicable to the proposed ANDA product or labeling. A patent’s existence alone does not establish that a Paragraph IV certification is required.
References
-
U.S. Food and Drug Administration. (2023). NERLYNX (neratinib) tablets, prescribing information. FDA.
-
U.S. Patent and Trademark Office. (2018). U.S. Patent No. 10,035,788, Neratinib maleate polymorphs and methods of use thereof. USPTO.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
